JP2008545715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008545715A5 JP2008545715A5 JP2008513812A JP2008513812A JP2008545715A5 JP 2008545715 A5 JP2008545715 A5 JP 2008545715A5 JP 2008513812 A JP2008513812 A JP 2008513812A JP 2008513812 A JP2008513812 A JP 2008513812A JP 2008545715 A5 JP2008545715 A5 JP 2008545715A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- betacellulin
- effective amount
- therapeutically effective
- situation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100001432 BTC Human genes 0.000 claims 6
- 101700038892 BTC Proteins 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 230000001154 acute Effects 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 101700077246 EHMT1 Proteins 0.000 claims 1
- 102100003818 GCG Human genes 0.000 claims 1
- 101710042131 GCG Proteins 0.000 claims 1
- 101710004768 GER5 Proteins 0.000 claims 1
- 101710004110 GLP Proteins 0.000 claims 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims 1
- 101700022962 HSP12 Proteins 0.000 claims 1
- 108010057186 Insulin Glargine Proteins 0.000 claims 1
- 108010065920 Insulin Lispro Proteins 0.000 claims 1
- 229960003105 Metformin Drugs 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 101710042151 Os01g0681900 Proteins 0.000 claims 1
- 101710039481 Os03g0179100 Proteins 0.000 claims 1
- 101700078733 ZGLP1 Proteins 0.000 claims 1
- 201000006233 congestive heart failure Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 201000004193 respiratory failure Diseases 0.000 claims 1
Claims (10)
- ベータセルリンの治療的有効量を含む、患者における急性の高血糖症の治療のための組成物。
- 前記急性の高血糖症が、心筋梗塞、呼吸不全、うっ血性心不全、および急性のグルコース代償不全から選択される少なくとも１つの病態による、請求項１に記載の組成物。
- 前記組成物が、緊急状況、集中治療状況、または病院外の状況における投与のためのものであることにより特徴付けられる、請求項１に記載の組成物。
- インスリン、リスプロ、グラルギン、ＧＬＰ１、およびメトホルミンから選択される少なくとも１つの追加の治療剤と組み合わせて投与されることにより特徴付けられる、請求項１に記載の組成物。
- 前記組成物がインスリンの使用を減らすかまたは皆無にする、請求項１に記載の組成物。
- 前記ベータセルリンの治療的有効量が、約０．０１ｍｇ／ｋｇと約５ｍｇ／ｋｇとの間である、請求項１に記載の組成物。
- 前記ベータセルリンの治療的有効量が、約０．１ｍｇ／ｋｇと約２ｍｇ／ｋｇとの間である、請求項６に記載の組成物。
- 前記ベータセルリンの治療的有効量が、約０．２ｍｇ／ｋｇと約１ｍｇ／ｋｇとの間である、請求項６に記載の組成物。
- 前記ベータセルリンの治療的有効量が、約０．３ｍｇ／ｋｇと約０．９ｍｇ／ｋｇとの間である、請求項６に記載の組成物。
- 前記ベータセルリンの治療的有効量が、約０．５ｍｇ／ｋｇと約０．７ｍｇ／ｋｇとの間である、請求項６に記載の組成物。
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68570205P | 2005-05-27 | 2005-05-27 | |
| US70206505P | 2005-07-22 | 2005-07-22 | |
| US70149005P | 2005-07-22 | 2005-07-22 | |
| US70196405P | 2005-07-22 | 2005-07-22 | |
| US73379105P | 2005-11-07 | 2005-11-07 | |
| US73686605P | 2005-11-16 | 2005-11-16 | |
| US77816906P | 2006-02-27 | 2006-02-27 | |
| US80044306P | 2006-05-16 | 2006-05-16 | |
| US11/442,244 US20070054851A1 (en) | 2005-05-27 | 2006-05-30 | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases |
| PCT/US2006/020797 WO2006128125A2 (en) | 2005-05-27 | 2006-05-30 | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008545715A JP2008545715A (ja) | 2008-12-18 |
| JP2008545715A5 true JP2008545715A5 (ja) | 2009-09-10 |
Family
ID=37452973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008513812A Pending JP2008545715A (ja) | 2005-05-27 | 2006-05-30 | 筋細胞へのグルコース取り込みを刺激する方法および組成物ならびに疾患を治療する方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070054851A1 (ja) |
| EP (1) | EP1890722A2 (ja) |
| JP (1) | JP2008545715A (ja) |
| AU (1) | AU2006249327A1 (ja) |
| CA (1) | CA2609728A1 (ja) |
| WO (1) | WO2006128125A2 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010513321A (ja) * | 2006-12-22 | 2010-04-30 | ノヴェリクス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 少なくとも一種の上皮細胞増殖因子受容体特異抗体またはその誘導体を用いる糖尿病の治療 |
| EP2173407B1 (en) * | 2007-07-02 | 2020-02-19 | Roche Diabetes Care GmbH | A device for drug delivery |
| US20090156488A1 (en) * | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| US20090147006A1 (en) * | 2007-12-07 | 2009-06-11 | Roche Diagnostics Operations, Inc. | Method and system for event based data comparison |
| CN102139095A (zh) * | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| WO2011146902A1 (en) | 2010-05-21 | 2011-11-24 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| RU2012157572A (ru) * | 2010-05-28 | 2014-07-10 | МЕН-ЭнЭрЖ СА | Изоформы нейрегулина, полипептиды нейрегулина и их применение |
| US20130217778A1 (en) * | 2010-07-21 | 2013-08-22 | Herman H. Vandenburgh | Methods and compositions for the improvement of skeletal muscle function in a mammal |
| CN102145164B (zh) * | 2010-12-16 | 2013-02-27 | 深圳市健元医药科技有限公司 | 一种更加稳定的iapp类似物注射剂 |
| UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| EP3527990A1 (en) | 2011-07-28 | 2019-08-21 | metanomics GmbH | Use of sm_sphingomyelin (d18:1, c23:1) as a marker for heart failure |
| CN115960249A (zh) | 2015-10-02 | 2023-04-14 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
| JP6935403B2 (ja) * | 2015-12-22 | 2021-09-15 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | サルコペニア及びフレイルの処置方法 |
| KR101908056B1 (ko) | 2017-05-25 | 2018-12-18 | 가천대학교 산학협력단 | 근아세포의 전기적 임피던스 모니터링 시스템 및 방법 |
| EP4126000A1 (en) * | 2020-03-31 | 2023-02-08 | Universität Heidelberg | Agents for use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE145939T1 (de) * | 1992-02-10 | 1996-12-15 | Takeda Chemical Industries Ltd | Mitogen für die glatte muskulatur und dessen kodierende dns |
| CN1202112A (zh) * | 1995-11-09 | 1998-12-16 | 武田药品工业株式会社 | 增强胰腺功能的组合物 |
| JP3945846B2 (ja) * | 1995-11-09 | 2007-07-18 | 武田薬品工業株式会社 | 膵臓機能改善剤 |
| PT1148129E (pt) * | 1998-12-09 | 2007-09-05 | Takeda Pharmaceutical | Modificação de betacelulina |
| JP4794049B2 (ja) * | 1999-04-06 | 2011-10-12 | ジェネンテック， インコーポレイテッド | 糖尿病治療へのＥｒｂＢレセプターリガンドの使用 |
| EP1176870B1 (en) * | 1999-04-26 | 2007-06-13 | Applied Protein Sciences, LLC | Tgf-alpha polypeptides, functional fragments and methods of use therefor |
| US6815418B2 (en) * | 1999-08-19 | 2004-11-09 | Kaleidos Pharma, Inc. | TGF-α polypeptides, functional fragments and methods of use therefor |
| AUPQ496900A0 (en) * | 2000-01-06 | 2000-02-03 | Gropep Pty Ltd | Growth factor splice variant |
| ES2370875T3 (es) * | 2000-05-23 | 2011-12-23 | Acorda Therapeutics, Inc. | Moléculas de ácido nucleico nrg-2, polipéptidos y métodos de diagnóstico y terapéuticos. |
| US20040132679A1 (en) * | 2002-09-03 | 2004-07-08 | Baylor College Of Medicine | Induction of pancreatic islet formation |
| CN1744916A (zh) * | 2002-12-04 | 2006-03-08 | 橘生药品工业株式会社 | 预防和治疗高血糖所导致的疾病 |
-
2006
- 2006-05-30 EP EP06760525A patent/EP1890722A2/en not_active Withdrawn
- 2006-05-30 JP JP2008513812A patent/JP2008545715A/ja active Pending
- 2006-05-30 AU AU2006249327A patent/AU2006249327A1/en not_active Abandoned
- 2006-05-30 WO PCT/US2006/020797 patent/WO2006128125A2/en active Application Filing
- 2006-05-30 US US11/442,244 patent/US20070054851A1/en not_active Abandoned
- 2006-05-30 CA CA002609728A patent/CA2609728A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008545715A5 (ja) | ||
| JP2020033360A5 (ja) | ||
| JP2018131450A5 (ja) | ||
| JP2010530001A5 (ja) | ||
| NZ710575A (en) | Pharmaceutical compositions for the treatment of diabetes mellitus | |
| JP2013541576A5 (ja) | ||
| BRPI0818687A2 (pt) | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. | |
| NO20084919L (no) | Oksadiazolidindionforbindelse | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| JP2011241213A5 (ja) | ||
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| NZ594044A (en) | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics | |
| JP2011529083A5 (ja) | ||
| JP2019517542A5 (ja) | ||
| MX2011007371A (es) | Metodo para tratar la hiperglucemia con la molecula. | |
| WO2007139941A3 (en) | Composition and methods for treatment of congestive heart failure | |
| MX336657B (es) | Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. | |
| JP2009500045A5 (ja) | ||
| JP2008545703A5 (ja) | ||
| RS52629B (en) | LIXISENATIDE AS ADDITIONAL THERAPY INSULIN GLARGINE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | |
| ES2922551T3 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| JP2018509419A5 (ja) | ||
| NZ591408A (en) | Paracetamol and Calcium carbonate composition | |
| JP2007119497A5 (ja) | ||
| RU2020140694A (ru) | Способ лечения гипергликемии |